Neurocrine Biosciences Inc at Stifel Healthcare Conference Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : <_ALACRA_META_ABSTRACT>Yes, that sounds great. Well, we had a really good conversation yesterday too about crinecerfont that I want to go back through because I thought that was an opportunity to dig deeper than you guys had before. But yes, maybe to start, I mean, I think at this point, right, Neurocrine, I look at you guys as one of the leading companies in the space. And when I have a question on what's happening here or there like you, Kyle, like -- I mean, your opinion matters. And so in the context of that, how is Neurocrine looking at the news right now? Who might be the head of HHS and RK Junior? What might happen at the FDA? What does the conversation look like inside of a company of yours? And how do you kind of plan strategically for this uncertainty?

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : You're not -- I mean, not that I know, not that you would say, but just strategically, right, you're not really looking to do a meaningful transaction in the short term. But if you were, would this kind of environment make you pause and just wait and see for three to four months?

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : Is there anything else outside of the FDA with all of this that could impact Neurocrine, I mean, changing policy or attitudes towards the mental health space? I mean, I don't want to get too far theoretical, right, but you can go googling around for different quotes online and from some of these candidates and find lots of different things that could theoretically impact something here or there.

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : Yes. Okay. Great. Let's talk a bit about crinecerfont. Eric, you had some really interesting perspectives on just the care dynamics in this as it relates to COEs, the sort of Tier 2 major centers, the pediatric market versus the adult market being more fragmented. Do you want to just sort of set the stage and talk about everything you've learned about CAH to date and -- maybe everything. You know it, sorry. Set the stage and talk about some of the things you've learned about CAH to date and give me some time to ask questions to go for 22 minutes.

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : With some of the recent rare disease launches like DAYBUE and SKYCLARYS, we've seen like a pretty significant patient bolus, and then this leveling off and almost kind of like a like a gap, right? And then we'll see where those drugs go from there. Do you think that this launch would follow those kinds of kinetics? Or is CAH just totally different than those analogs?

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : From a payer perspective, Eric, you've talked about doing engagement, educating payers. You feel like they appreciate the value of reducing steroids. Again, using some of these recent drugs as analogs like DAYBUE and SKYCLARYS, like do you feel like we're in the right ballpark with those as it relates to the potential annual cost of crinecerfont?

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : DAYBUE and SKYCLARYS.

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : Neurocrine usually sandbags expectations. Should we expect like 700,000 --?

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : You thought about what metrics you might share given the potential lag in revenues versus demand?

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : Yes. Okay. Great. Let's talk maybe about INGREZZA. I asked you a question last night, how long can INGREZZA grow at 20% per year, right, which again is a loaded question, but is a testament to your continued view that you're underpenetrated in this market. Do you want to talk a little bit about that? I mean do you feel like what you're seeing right now in terms of this patient add rate is sustainable in the midterm?

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : Are you as enthusiastic as you were a couple of weeks ago about making a big multi-pivotal study investment in the M4 after what happen with emraclidine?

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : Right, and not in between.

Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst : Great. I think we're out of time, but thank you guys very much. Appreciate it. It's great seeing you. Yes.